MX2021007707A - Niveles de farmacos locales sostenidos para los agonistas inmunitarios innatos. - Google Patents

Niveles de farmacos locales sostenidos para los agonistas inmunitarios innatos.

Info

Publication number
MX2021007707A
MX2021007707A MX2021007707A MX2021007707A MX2021007707A MX 2021007707 A MX2021007707 A MX 2021007707A MX 2021007707 A MX2021007707 A MX 2021007707A MX 2021007707 A MX2021007707 A MX 2021007707A MX 2021007707 A MX2021007707 A MX 2021007707A
Authority
MX
Mexico
Prior art keywords
prra
innate immune
drug levels
acceptable salt
water
Prior art date
Application number
MX2021007707A
Other languages
English (en)
Inventor
Nicola Bisek
Tobias Voigt
Samuel Weisbrod
Sebastian Stark
Torben Lessmann
Juha Punnonen
Lars Holten-Andersen
Kennett Sprogøe
David B Rosen
Luis Zuniga
Yang Yang-Malten
Original Assignee
Ascendis Pharma Oncology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Oncology Div A/S filed Critical Ascendis Pharma Oncology Div A/S
Publication of MX2021007707A publication Critical patent/MX2021007707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un agonista del receptor de reconocimiento de patrones ("PRRA") de liberación controlada e insoluble en agua o a su sal farmacéuticamente aceptable o a una composición farmacéutica que comprende tal PRRA de liberación controlada e insoluble en agua o su sal farmacéuticamente aceptable para usarse en el tratamiento de un trastorno de proliferación celular, en el que el PRRA de liberación controlada e insoluble en agua, su sal farmacéuticamente aceptable o la composición farmacéutica se administran por vía intratisular, y en el que al menos el 25% de la cantidad de PRRA permanece localmente en tal tejido 3 días después de la administración; y a aspectos relacionados.
MX2021007707A 2019-01-04 2020-01-03 Niveles de farmacos locales sostenidos para los agonistas inmunitarios innatos. MX2021007707A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19150388 2019-01-04
EP19181823 2019-06-21
EP19206471 2019-10-31
PCT/EP2020/050095 WO2020141222A1 (en) 2019-01-04 2020-01-03 Sustained local drug levels for innate immune agonists

Publications (1)

Publication Number Publication Date
MX2021007707A true MX2021007707A (es) 2021-08-05

Family

ID=69147693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007707A MX2021007707A (es) 2019-01-04 2020-01-03 Niveles de farmacos locales sostenidos para los agonistas inmunitarios innatos.

Country Status (12)

Country Link
US (1) US20220054476A1 (es)
EP (1) EP3906032A1 (es)
JP (1) JP2022516314A (es)
KR (1) KR20210113272A (es)
CN (1) CN113316452A (es)
AU (1) AU2020204785A1 (es)
BR (1) BR112021010043A2 (es)
CA (1) CA3125479A1 (es)
IL (1) IL284436A (es)
MX (1) MX2021007707A (es)
SG (1) SG11202104966XA (es)
WO (1) WO2020141222A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023110727A2 (en) * 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
ES2512499T3 (es) 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Fármacos pegilados reversibles
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
DK1732607T3 (da) 2004-03-23 2019-07-22 Ascendis Pharma Gmbh Polymer-prodrug med en selvofrende linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
KR20090055623A (ko) 2006-09-15 2009-06-02 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
DK2237799T3 (da) 2008-02-01 2019-06-11 Ascendis Pharma As Prodrug omfattende en selv-spaltbar linker
CA2723263A1 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
CA2769162C (en) 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011082368A2 (en) 2009-12-31 2011-07-07 Enzon Pharmaceuticals, Inc Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
IN2014CN00989A (es) 2011-08-12 2015-04-10 Ascendis Pharma As
AU2012296955B2 (en) 2011-08-12 2016-12-15 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
MX2014003993A (es) 2011-10-12 2014-08-08 Ascendis Pharma Ophthalmology Division As Prevencion y tratamiento de condiciones oculares.
AU2013254756B2 (en) 2012-04-25 2017-03-30 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
RU2647729C2 (ru) 2012-10-11 2018-03-19 Асцендис Фарма Ас Пролекарства на основе гидрогеля
WO2016020373A1 (en) 2014-08-06 2016-02-11 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
DK3653227T5 (da) 2014-11-18 2023-08-21 Ascendis Pharma Endocrinology Div A/S Hidtil ukendte polymere hgh-prodrugs
SG10202107829YA (en) 2017-03-22 2021-08-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
IL308797A (en) 2018-03-28 2024-01-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates

Also Published As

Publication number Publication date
CA3125479A1 (en) 2020-07-09
JP2022516314A (ja) 2022-02-25
IL284436A (en) 2021-08-31
US20220054476A1 (en) 2022-02-24
BR112021010043A2 (pt) 2021-10-26
WO2020141222A1 (en) 2020-07-09
EP3906032A1 (en) 2021-11-10
SG11202104966XA (en) 2021-06-29
CN113316452A (zh) 2021-08-27
AU2020204785A1 (en) 2021-06-03
KR20210113272A (ko) 2021-09-15

Similar Documents

Publication Publication Date Title
Chindalore et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
JP2009541237A (ja) 様々な型の痛みを予防、軽減及び／又は治療する医薬を製造するための、置換２−アミノテトラリンの使用
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
CA2972379A1 (en) Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
MX2021007707A (es) Niveles de farmacos locales sostenidos para los agonistas inmunitarios innatos.
JP2016505050A5 (es)
EP3331509B1 (en) Stable liquid injectable solution of midazolam and pentazocine
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
JOP20220126A1 (ar) تركيبة صيدلانية لعلاج أمراض الأوعية الدموية الرئوية و/أو خلل وظيفي في القلب لمرضى فونتان المُخفّف
MX2019014675A (es) Solucion de levodopa para infusion.
DE60315490T2 (de) Therapeutische behandlung
JP7062804B2 (ja) レビー小体病の治療および／または予防剤
US20210393606A1 (en) Therapeutic agent for frontal lobe dysfunction
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
EA202090965A1 (ru) Водные композиции биластина
BR112018016817A2 (pt) composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento
JP7433331B2 (ja) 特発性肺線維症を治療するための組成物及び方法
KR20140043898A (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
JP2020033322A (ja) パーキンソン病の治療のための医薬組成物